India's IP Protections Judged By Novartis Not Worth R&D Effort
This article was originally published in PharmAsia News
Executive Summary
India has been downgraded as a research-and-development site for Novartis of Switzerland, the drug maker complaining of patent challenges still allowed by the nation's laws